Search

Search Constraints

You searched for: Author/Creator Castagnetti, Fausto

Search Results

11. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. Issue 11 (30th May 2017)

12. Health‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib. Issue 10 (2nd March 2018)

14. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. Issue 1 (December 2016)

15. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Issue 2 (19th July 2012)

16. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. Issue 2 (February 2014)

17. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. (15th February 2020)

18. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. (16th February 2021)

19. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. (16th February 2021)

20. Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. Issue 2 (28th January 2020)